Publication Name	World Journal of Cardiology
Manuscript ID	65949
Country	Japan

Received	2021-03-21 01:34
Peer-Review Started	2021-03-21 01:37
To Make the First Decision
Return for Revision	2021-05-06 00:00
Revised	2021-05-11 09:51
Second Decision	2021-07-23 03:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-07-23 06:44
Articles in Press	2021-07-23 06:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-13 08:16
Publish the Manuscript Online	2021-09-18 06:37

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
Manuscript Source	Invited Manuscript
All Author List	Ryo Naito and Takatoshi Kasai
ORCID	Author(s) ORCID Number Ryo Naito http://orcid.org/0000-0003-3348-2125 Takatoshi Kasai http://orcid.org/0000-0001-5747-7668
Funding Agency and Grant Number
Corresponding Author	Takatoshi Kasai, MD, PhD, Associate Professor, Department of Cardiovascular Biology and Medicine, Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine; Sleep and Sleep Disordered Breathing Center, Juntendo University Hospital, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan. kasai-t@mx6.nisiq.net
Key Words	Sodium glucose cotransporter 2 inhibitors; Heart failure; Clinical trials; Potential mechanisms; Diuretics
Core Tip	Sodium glucose cotransporter 2 inhibitors are newly approved by the Food and Drug Administration as treatment choice for heart failure based on evidence from several large-scale clinical trials demonstrating reduction in cardiovascular outcomes, especially hospitalization for heart failure or cardiovascular death. The background of the approval and potential mechanisms are discussed in this review. As well, summary of available evidence from clinical trials and ongoing trials examining beneficial effects of the agents are written.
Publish Date	2021-09-18 06:37
Citation	Naito R, Kasai T. Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World J Cardiol 2021; 13(9): 464-471
URL	https://www.wjgnet.com/1949-8462/full/v13/i9/464.htm
DOI	https://dx.doi.org/10.4330/wjc.v13.i9.464

Full Article (PDF)	WJC-13-464.pdf
Full Article (Word)	WJC-13-464.docx
Manuscript File	65949_Auto_Edited-JPY.docx
Answering Reviewers	65949-Answering reviewers.pdf
Audio Core Tip	65949-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	65949-Conflict-of-interest statement.pdf
Copyright License Agreement	65949-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	65949-Language certificate.pdf
Peer-review Report	65949-Peer-review(s).pdf
Scientific Misconduct Check	65949-Scientific misconduct check.pdf
Scientific Editor Work List	65949-Scientific editor work list.pdf
CrossCheck Report	65949-CrossCheck report.pdf